GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (TSXV:IPA) » Definitions » Gross Margin %

ImmunoPrecise Antibodies (TSXV:IPA) Gross Margin % : 48.03% (As of Oct. 2023)


View and export this data going back to 1986. Start your Free Trial

What is ImmunoPrecise Antibodies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ImmunoPrecise Antibodies's Gross Profit for the three months ended in Oct. 2023 was C$2.95 Mil. ImmunoPrecise Antibodies's Revenue for the three months ended in Oct. 2023 was C$6.15 Mil. Therefore, ImmunoPrecise Antibodies's Gross Margin % for the quarter that ended in Oct. 2023 was 48.03%.


The historical rank and industry rank for ImmunoPrecise Antibodies's Gross Margin % or its related term are showing as below:

TSXV:IPA' s Gross Margin % Range Over the Past 10 Years
Min: 45.05   Med: 55.95   Max: 64.42
Current: 53.27


During the past 13 years, the highest Gross Margin % of ImmunoPrecise Antibodies was 64.42%. The lowest was 45.05%. And the median was 55.95%.

TSXV:IPA's Gross Margin % is ranked worse than
55.84% of 736 companies
in the Biotechnology industry
Industry Median: 59.905 vs TSXV:IPA: 53.27

ImmunoPrecise Antibodies had a gross margin of 48.03% for the quarter that ended in Oct. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ImmunoPrecise Antibodies was 4.90% per year.


ImmunoPrecise Antibodies Gross Margin % Historical Data

The historical data trend for ImmunoPrecise Antibodies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Gross Margin % Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec13 Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.46 57.15 64.41 56.72 55.95

ImmunoPrecise Antibodies Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.61 57.32 59.44 49.14 48.03

Competitive Comparison of ImmunoPrecise Antibodies's Gross Margin %

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Gross Margin % falls into.



ImmunoPrecise Antibodies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

ImmunoPrecise Antibodies's Gross Margin for the fiscal year that ended in Apr. 2023 is calculated as

Gross Margin % (A: Apr. 2023 )=Gross Profit (A: Apr. 2023 ) / Revenue (A: Apr. 2023 )
=11.6 / 20.665
=(Revenue - Cost of Goods Sold) / Revenue
=(20.665 - 9.102) / 20.665
=55.95 %

ImmunoPrecise Antibodies's Gross Margin for the quarter that ended in Oct. 2023 is calculated as


Gross Margin % (Q: Oct. 2023 )=Gross Profit (Q: Oct. 2023 ) / Revenue (Q: Oct. 2023 )
=3 / 6.15
=(Revenue - Cost of Goods Sold) / Revenue
=(6.15 - 3.196) / 6.15
=48.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ImmunoPrecise Antibodies  (TSXV:IPA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ImmunoPrecise Antibodies had a gross margin of 48.03% for the quarter that ended in Oct. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


ImmunoPrecise Antibodies Gross Margin % Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies (TSXV:IPA) Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from Europe.